Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early.

Trial Profile

Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary) ; Paclitaxel (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms LAPADO
  • Most Recent Events

    • 14 Jan 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials database
    • 12 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top